FUTURE INDICATIONS & EXPANSIONS
Where the Next Era of Radiopharmaceuticals Is Headed and How CyGen Will Lead It
The Next Frontier of Alpha-Therapy Cancers (2025–2035)
Alpha therapy is rapidly transitioning from early niche applications into large, high-value oncology markets. Today’s anchor indications (prostate cancer, NETs, hematologic malignancies) represent only a fraction of the clinical potential for Ac-225, At-211, and Pb-212.
Breast Cancer (HER2+, Triple-Negative, and Male Breast Cancer)
Why it’s a major future indication:
Breast cancer expresses several highly targetable biomarkers (HER2, MUC1, EGFR variants). Multiple alpha-emitter programs are already pairing these targets with Ac-225 and Pb-212, demonstrating potent tumor kill even in resistant or metastatic disease.
Why CyGen matters:
At-211’s extremely short path length (40–80 microns) makes it ideal for micro-metastatic lesions common in breast cancer. Meanwhile, Cu-64 PET imaging is already being explored for HER2-positive disease, enabling precise treatment planning.
Colorectal Cancer
Why it’s emerging:
Colorectal tumors frequently express CEA and MUC1 — two ligands with active alpha-therapy programs. Lead-212 conjugates in particular have shown promise in early studies for peritoneal metastatic spread.
Why CyGen matters:
Future TATs for colorectal cancer will require reliable Pb-212 generators and Ac-225 supply — both central to CyGen’s platform. Cu-64 PET also enables immuno-PET mapping of treatment responders.
Pancreatic Cancer
Why it’s a priority cancer:
One of the deadliest cancers, largely because it is diagnosed late and is resistant to chemotherapy. Several alpha agents targeting FAP, CLDN18.2, and other tumor markers are advancing through preclinical and early clinical pipelines.
Why CyGen matters:
Pancreatic tumors sit deep in the abdomen, ideal for a short-range, high-energy alpha emitter like Ac-225 that spares healthy tissue. The ability to pair diagnostic Cu-64 imaging with therapeutic alpha isotopes is a step toward adaptive, precision therapy.
Bladder & Kidney (Renal Cell) Cancer
Why these cancers are rising into TAT feasibility:
Renal cell carcinoma expresses CAIX and other ligands with strong alpha-therapy pairing potential. Bladder tumors, especially recurrent ones, are excellent candidates for short-range isotopes like At-211.
Why CyGen matters:
These cancers could become some of the earliest solid-tumor approvals for alpha therapies beyond prostate cancer. CyGen’s ability to supply multiple isotopes under one GMP facility gives pharma partners flexibility to test and scale.
Head & Neck Cancers (Oral Cavity, Oropharynx, Thyroid-Related)
Why these are promising for alphas:
These tumors often express EGFR and PSMA variants, making them excellent candidates for targeted alpha therapy. Surgical complexity and local recurrence risks make precision radiation highly valuable.
Why CyGen matters:
At-211 is particularly suited for superficial or regionally contained disease. Reliable isotope delivery within hours, something CyGen will provide in the the Southern US, is essential due to short half-life constraints.
Ovarian Cancer
Why it’s strategically important:
Ovarian cancer frequently presents with widespread micro-metastases throughout the abdomen — extremely difficult to treat surgically or with chemotherapy. Alpha particles, which kill cell-by-cell with minimal spread, are a potential breakthrough.
Why CyGen matters:
Pb-212-based therapies are already being studied in ovarian cancer. CyGen’s platform intentionally includes theranostic isotopes that allow paired imaging + treatment programs.
Brain & CNS Tumors (including Glioblastoma)
Why this may be one of the biggest breakthroughs:
At-211 was originally conceived for CNS cancers due to its extremely short path length and ability to be delivered intra-operatively or via convection-enhanced delivery. Early studies show strong tumoricidal effect without damaging surrounding brain tissue.
Why CyGen matters:
CyGen will be one of the only private facilities in the U.S. capable of producing meaningful therapeutic At-211 volumes for clinical use. This alone will attract research groups from across the country.